A Phase 3 interventional study of Placebo and Aliskiren 150 mg tablet in Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 18 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-06-06.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies testing aliskiren in Hypertension — none open to participants now, none under way, none of them phase 3. aliskiren · Hypertension.
Among the 89 studies testing aliskiren in Hypertension, this one is the 2nd largest by enrollment, is one of 12 that started in 2008, is one of 38 in phase 3, and was the 47th registered.
6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.
Browse Hypertension studies →None of the 89 studies testing aliskiren in Hypertension is open now. The open studies under Hypertension, anywhere →
aliskiren: first FDA approval 2007 (TEKTURNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 39 · Phase 4 34
First in 2001; this study’s year is marked. 12 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,694 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 253 across the 89 interventional studies. Of the 79 that completed or were terminated, 36 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
65 of 89 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
228 studies in Hypertension by Novartis: 5 open now, 6 under way, none of them phase 3. Of 219 finished, 88 (40%) have results posted.
Among the 228 studies in Hypertension by Novartis, this one is the 6th largest by enrollment of the 223 interventional ones that give a count, is one of 25 that started in 2008, is one of 108 in phase 3, and was the 142nd registered.
Novartis’s Hypertension studies by the year they started, since 1989.
None of the studies under way reaches primary completion within a year.
Among the 89 studies testing aliskiren in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 228 in Hypertension:
This tab as a report to print or save as PDF → With an account.
Evaluate the efficacy (blood pressure lowering effect) and safety of aliskiren alone and in combination with amlodipine in patients with essential hypertension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 5 of the 5 pills taken were placebos.
Drug: Placebo
Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
Drug: Placebo · Drug: Aliskiren 150 mg tablet
Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
Drug: Placebo · Drug: Aliskiren 300 mg tablet
Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
Drug: Placebo · Drug: Amlodipine 5 mg capsule
Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos. Amlodipine 10 mg arm starts with 1 week of Amlodipine 5 mg, then force titrated to 10 mg
Drug: Placebo · Drug: Amlodipine 10 mg capsule
Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
Drug: Placebo · Drug: Aliskiren/amlodipine 150/5 mg tablet
150/5 for 1 week, then up-titrated to 150/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
Drug: Placebo · Drug: Aliskiren/amlodipine 150/10 mg tablet
Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
Drug: Placebo · Drug: Aliskiren/amlodipine 300/5 mg tablet
300/5 for 1 week, then up-titrated to 300/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
Drug: Placebo · Drug: Aliskiren/amlodipine 300/10 mg tablet
Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Aliskiren 150 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
Time frame: Baseline to end of study (Week 8)
Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
Time frame: Baseline to end of study (Week 8)
Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP)
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
Time frame: Baseline to end of study (Week 8)
Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Aliskiren 150 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
Time frame: Baseline to end of study (Week 8)
Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
Time frame: Baseline to end of study (Week 8)
Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP)
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
Time frame: Baseline to end of study (Week 8)
Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Aliskiren 300 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
Time frame: Baseline to end of study (Week 8)
Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
Time frame: Baseline to end of study (Week 8)
Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP)
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
Time frame: Baseline to end of study (Week 8)
Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Aliskiren 300 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
Time frame: Baseline to end of study (Week 8)
Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
Time frame: Baseline to end of study (Week 8)
Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP)
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
Time frame: Baseline to end of study (Week 8)
Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Aliskiren 150 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
Time frame: Baseline to end of study (Week 8)
Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
Time frame: Baseline to end of study (Week 8)
Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Placebo on Change in Mean Sitting Systolic Blood Pressure (msSBP)
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
Time frame: Baseline to end of study (Week 8)
Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Aliskiren 150 mg on Change in Mean Sitting Systolic Blood Pressure (mssBP)
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
Time frame: Baseline to end of study (Week 8)
Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
Time frame: Baseline to end of study (Week 8)
Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Placebo on Change in Mean Sitting Systolic Blood Pressure (msSBP)
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
Time frame: Baseline to end of study (Week 8)
Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Aliskiren 300 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
Time frame: Baseline to end of study (Week 8)
Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
Time frame: Baseline to end of study (Week 8)
Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Placebo on Change in Mean Sitting Systolic Blood Pressure (msSBP)
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
Time frame: Baseline to end of study (Week 8)
Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Aliskiren 300 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
Time frame: Baseline to end of study (Week 8)
Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
Time frame: Baseline to end of study (Week 8)
Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Placebo on Change in Mean Sitting Systolic Blood Pressure (msSBP)
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
Time frame: Baseline to end of study (Week 8)
Percentage of Patients With Blood Pressure Control (msSBP < 140 mm Hg and msDBP < 90 mm Hg) at End of Study
Blood pressure control defined as msSBP \< 140 mm Hg and msDBP \< 90 mm Hg. The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
Time frame: End of study (Week 8)
Percentage of Patients Achieving a Successful Diastolic Blood Pressure Response
Blood pressure response in msDBP is defined as a mean sitting diastolic blood pressure \< 90 mmHg or a \>=10 mmHg reduction from baseline. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
Time frame: End of study (Week 8)
Percentage of Patients Achieving a Successful Systolic Blood Pressure Response
Blood pressure response in msSBP is defined as a mean sitting systolic blood pressure \< 140 mmHg or a \>= 20 mmHg reduction from baseline. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
Time frame: End of study (Week 8)
A total of 2694 patients enrolled in the single-blind, placebo run-in period (2 to 4 weeks) of the study. A total of 1688 patients were randomized into the double-blind treatment period (8 weeks). Three patients were mis-randomized, as they were discontinued from the single-blind period and were not treated in the double-blind period.
| Milestone | Placebo | Aliskiren 150 mg | Aliskiren 300 mg | Amlodipine 5 mg | Amlodipine 10 mg | Aliskiren/Amlodipine 150/5 mg | Aliskiren/Amlodipine 150/10 mg | Aliskiren/Amlodipine 300/5 mg | Aliskiren/Amlodipine 300/10 mg Tablet |
|---|---|---|---|---|---|---|---|---|---|
| Started | 2694 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 1685 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 1009 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 35 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Abnormal laboratory value(s) | 38 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Abnormal test procedure result(s) | 810 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Patient withdrew consent | 86 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 17 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Administrative problems | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo | Aliskiren 150 mg | Aliskiren 300 mg | Amlodipine 5 mg | Amlodipine 10 mg | Aliskiren/Amlodipine 150/5 mg | Aliskiren/Amlodipine 150/10 mg | Aliskiren/Amlodipine 300/5 mg | Aliskiren/Amlodipine 300/10 mg Tablet |
|---|---|---|---|---|---|---|---|---|---|
| Started | 198 | 195 | 203 | 185 | 181 | 181 | 183 | 178 | 184 |
| Completed | 168 | 175 | 184 | 173 | 162 | 169 | 170 | 168 | 170 |
| Not completed | 30 | 20 | 19 | 12 | 19 | 12 | 13 | 10 | 14 |
| Withdrew: Adverse event | 3 | 3 | 1 | 2 | 7 | 3 | 4 | 1 | 4 |
| Withdrew: Abnormal laboratory values | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Abnormal test procedure results | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Unsatisfactory therapeutic effect | 17 | 8 | 8 | 4 | 2 | 2 | 1 | 1 | 2 |
| Withdrew: Patient no longer needs study drug | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Patient withdrew consent | 4 | 2 | 4 | 3 | 4 | 4 | 3 | 2 | 4 |
| Withdrew: Lost to follow-up | 0 | 2 | 4 | 1 | 2 | 2 | 0 | 3 | 1 |
| Withdrew: Administrative problems | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Protocol deviation | 5 | 3 | 1 | 2 | 3 | 1 | 2 | 2 | 3 |
| Withdrew: Discont. single-blind, mis- randomized | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
| mm Hg | Aliskiren 150 mg | Aliskiren/Amlodipine 150/5 mg |
|---|---|---|
| Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Aliskiren 150 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP) | -10.67 ± 1.01 | -20.64 ± 1.05 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
| mm Hg | Amlodipine 5 mg | Aliskiren/Amlodipine 150/5 mg |
|---|---|---|
| Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP) | -15.82 ± 1.04 | -20.64 ± 1.05 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
| mm Hg | Placebo | Aliskiren/Amlodipine 150/5 mg |
|---|---|---|
| Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Placebo on Change in Mean Sitting Systolic Blood Pressure (msSBP) | -6.79 ± 1.00 | -20.64 ± 1.05 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
| mm Hg | Aliskiren 150 mg | Aliskiren/Amlodipine 150/10 mg |
|---|---|---|
| Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Aliskiren 150 mg on Change in Mean Sitting Systolic Blood Pressure (mssBP) | -10.67 ± 1.01 | -23.87 ± 1.05 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
| mm Hg | Aliskiren 150 mg | Aliskiren/Amlodipine 150/5 mg |
|---|---|---|
| Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Aliskiren 150 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP) | -7.99 ± 0.63 | -13.98 ± 0.66 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
| mm Hg | Amlodipine 5 mg | Aliskiren/Amlodipine 150/5 mg |
|---|---|---|
| Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP) | -11.0 ± 0.65 | -13.98 ± 0.66 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
| mm Hg | Placebo | Aliskiren/Amlodipine 150/5 mg |
|---|---|---|
| Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP) | -5.35 ± 0.62 | -13.98 ± 0.66 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
| mm Hg | Aliskiren 150 mg | Aliskiren/Amlodipine 150/10 mg |
|---|---|---|
| Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Aliskiren 150 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP) | -7.99 ± 0.63 | -16.16 ± 0.66 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
| mm Hg | Amlodipine 10 mg | Aliskiren/Amlodipine 150/10 mg |
|---|---|---|
| Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP) | -13.82 ± 0.66 | -16.16 ± 0.66 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
| mm Hg | Placebo | Aliskiren/Amlodipine 150/10 mg |
|---|---|---|
| Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP) | -5.35 ± 0.62 | -16.16 ± 0.66 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
| mm Hg | Aliskiren 300 mg | Aliskiren/Amlodipine 300/5 mg |
|---|---|---|
| Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Aliskiren 300 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP) | -10.19 ± 0.62 | -14.99 ± 0.66 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
| mm Hg | Amlodipine 5 mg | Aliskiren/Amlodipine 300/5 mg |
|---|---|---|
| Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP) | -11.0 ± 0.65 | -14.99 ± 0.66 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
| mm Hg | Placebo | Aliskiren/Amlodipine 300/5 mg |
|---|---|---|
| Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP) | -5.35 ± 0.62 | -14.99 ± 0.66 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
| mm Hg | Aliskiren 300 mg | Aliskiren/Amlodipine 300/10 mg Tablet |
|---|---|---|
| Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Aliskiren 300 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP) | -10.19 ± 0.62 | -16.45 ± 0.65 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
| mm Hg | Amlodipine 10 mg | Aliskiren/Amlodipine 300/10 mg Tablet |
|---|---|---|
| Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP) | -13.82 ± 0.66 | -16.45 ± 0.65 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
| mm Hg | Placebo | Aliskiren/Amlodipine 300/10 mg Tablet |
|---|---|---|
| Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP) | -5.35 ± 0.62 | -16.45 ± 0.65 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
| mm Hg | Amlodipine 10 mg | Aliskiren/Amlodipine 150/10 mg |
|---|---|---|
| Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP) | -21.04 ± 1.05 | -23.87 ± 1.05 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
| mm Hg | Placebo | Aliskiren/Amlodipine 150/10 mg |
|---|---|---|
| Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Placebo on Change in Mean Sitting Systolic Blood Pressure (msSBP) | -6.79 ± 1.00 | -23.87 ± 1.05 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
| mm Hg | Aliskiren 300 mg | Aliskiren/Amlodipine 300/5 mg |
|---|---|---|
| Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Aliskiren 300 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP) | -15.37 ± 0.99 | -21.82 ± 1.06 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
| mm Hg | Amlodipine 5 mg | Aliskiren/Amlodipine 300/5 mg |
|---|---|---|
| Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP) | -15.82 ± 1.04 | -21.82 ± 1.06 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
| mm Hg | Placebo | Aliskiren/Amlodipine 300/5 mg |
|---|---|---|
| Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Placebo on Change in Mean Sitting Systolic Blood Pressure (msSBP) | -6.79 ± 1.00 | -21.82 ± 1.06 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
| mm Hg | Aliskiren 300 mg | Aliskiren/Amlodipine 300/10 mg Tablet |
|---|---|---|
| Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Aliskiren 300 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP) | -15.37 ± 0.99 | -23.19 ± 1.04 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
| mm Hg | Amlodipine 10 mg | Aliskiren/Amlodipine 300/10 mg Tablet |
|---|---|---|
| Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP) | -21.04 ± 1.05 | -23.19 ± 1.04 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
| mm Hg | Placebo | Aliskiren/Amlodipine 300/10 mg Tablet |
|---|---|---|
| Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Placebo on Change in Mean Sitting Systolic Blood Pressure (msSBP) | -6.79 ± 1.00 | -23.19 ± 1.04 |
Blood pressure control defined as msSBP \< 140 mm Hg and msDBP \< 90 mm Hg. The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
| Percentage of Participants | Placebo | Aliskiren 150 mg | Aliskiren 300 mg | Amlodipine 5 mg | Amlodipine 10 mg | Aliskiren/Amlodipine 150/5 mg | Aliskiren/Amlodipine 150/10 mg | Aliskiren/Amlodipine 300/5 mg | Aliskiren/Amlodipine 300/10 mg Tablet |
|---|---|---|---|---|---|---|---|---|---|
| Percentage of Patients With Blood Pressure Control (msSBP < 140 mm Hg and msDBP < 90 mm Hg) at End of Study | 19.2 | 26.9 | 36.3 | 35.9 | 50.3 | 49.2 | 65.4 | 56.5 | 68.3 |
Blood pressure response in msDBP is defined as a mean sitting diastolic blood pressure \< 90 mmHg or a \>=10 mmHg reduction from baseline. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
| Percentage of Participants | Placebo | Aliskiren 150 mg | Aliskiren 300 mg | Amlodipine 5 mg | Amlodipine 10 mg | Aliskiren/Amlodipine 150/5 mg | Aliskiren/Amlodipine 150/10 mg | Aliskiren/Amlodipine 300/5 mg | Aliskiren/Amlodipine 300/10 mg Tablet |
|---|---|---|---|---|---|---|---|---|---|
| Percentage of Patients Achieving a Successful Diastolic Blood Pressure Response | 34.3 | 50.3 | 54.2 | 62.0 | 74.3 | 73.2 | 83.8 | 73.7 | 84.7 |
Blood pressure response in msSBP is defined as a mean sitting systolic blood pressure \< 140 mmHg or a \>= 20 mmHg reduction from baseline. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.
| Percentage of Participants | Placebo | Aliskiren 150 mg | Aliskiren 300 mg | Amlodipine 5 mg | Amlodipine 10 mg | Aliskiren/Amlodipine 150/5 mg | Aliskiren/Amlodipine 150/10 mg | Aliskiren/Amlodipine 300/5 mg | Aliskiren/Amlodipine 300/10 mg Tablet |
|---|---|---|---|---|---|---|---|---|---|
| Percentage of Patients Achieving a Successful Systolic Blood Pressure Response | 32.3 | 41.5 | 53.2 | 54.9 | 72.1 | 67.6 | 77.1 | 69.7 | 80.3 |
Collected over Baseline to end of study (Week 8). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 2/198 (1%) | 22/198 (11.1%) |
| Aliskiren 150 mg Tablet | — | 0/194 (0%) | 15/194 (7.7%) |
| Aliskiren 300 mg Tablet | — | 0/203 (0%) | 18/203 (8.9%) |
| Amlodipine 5 mg Capsule | — | 1/185 (0.5%) | 18/185 (9.7%) |
| Amlodipine 10 mg Capsule | — | 1/181 (0.6%) | 32/181 (17.7%) |
| Aliskiren/Amlodipine 150/5 mg Tablet | — | 1/181 (0.6%) | 15/181 (8.3%) |
| Aliskiren/Amlodipine 150/10 mg Tablet | — | 2/181 (1.1%) | 19/181 (10.5%) |
| Aliskiren/Amlodipine 300/5 mg Tablet | — | 1/178 (0.6%) | 8/178 (4.5%) |
| Aliskiren/Amlodipine 300/10 mg Tablet | — | 1/184 (0.5%) | 30/184 (16.3%) |
| Event | Placebo | Aliskiren 150 mg Tablet | Aliskiren 300 mg Tablet | Amlodipine 5 mg Capsule | Amlodipine 10 mg Capsule | Aliskiren/Amlodipine 150/5 mg Tablet | Aliskiren/Amlodipine 150/10 mg Tablet | Aliskiren/Amlodipine 300/5 mg Tablet | Aliskiren/Amlodipine 300/10 mg Tablet |
|---|---|---|---|---|---|---|---|---|---|
| GastroenteritisInfections and infestations | 0/198 | 0/194 | 0/203 | 0/185 | 0/181 | 0/181 | 0/181 | 1/178 | 0/184 |
| BronchitisInfections and infestations | 0/198 | 0/194 | 0/203 | 0/185 | 0/181 | 0/181 | 1/181 | 0/178 | 0/184 |
| PneumoniaInfections and infestations | 0/198 | 0/194 | 0/203 | 1/185 | 1/181 | 0/181 | 0/181 | 0/178 | 0/184 |
| Cerebrovascular accidentNervous system disorders | 0/198 | 0/194 | 0/203 | 0/185 | 0/181 | 1/181 | 0/181 | 0/178 | 0/184 |
| Calculus uretericRenal and urinary disorders | 0/198 | 0/194 | 0/203 | 0/185 | 0/181 | 0/181 | 1/181 | 0/178 | 0/184 |
| HydronephrosisRenal and urinary disorders | 0/198 | 0/194 | 0/203 | 0/185 | 0/181 | 0/181 | 1/181 | 0/178 | 0/184 |
| Retinal detachmentEye disorders | 0/198 | 0/194 | 0/203 | 0/185 | 0/181 | 0/181 | 0/181 | 0/178 | 1/184 |
| Abdominal massGastrointestinal disorders | 1/198 | 0/194 | 0/203 | 0/185 | 0/181 | 0/181 | 0/181 | 0/178 | 0/184 |
| Hand fractureInjury, poisoning and procedural complications | 1/198 | 0/194 | 0/203 | 0/185 | 0/181 | 0/181 | 0/181 | 0/178 | 0/184 |
| Event | Placebo | Aliskiren 150 mg Tablet | Aliskiren 300 mg Tablet | Amlodipine 5 mg Capsule | Amlodipine 10 mg Capsule | Aliskiren/Amlodipine 150/5 mg Tablet | Aliskiren/Amlodipine 150/10 mg Tablet | Aliskiren/Amlodipine 300/5 mg Tablet | Aliskiren/Amlodipine 300/10 mg Tablet |
|---|---|---|---|---|---|---|---|---|---|
| Oedema peripheralGeneral disorders | 2/198 | 2/194 | 3/203 | 8/185 | 25/181 | 4/181 | 14/181 | 2/178 | 25/184 |
| HeadacheNervous system disorders | 20/198 | 13/194 | 15/203 | 11/185 | 8/181 | 11/181 | 8/181 | 6/178 | 5/184 |
| Age Continuous(years) | Placebo | Aliskiren 150 mg | Aliskiren 300 mg | Amlodipine 5 mg | Amlodipine 10 mg | Aliskiren/Amlodipine 150/5 mg | Aliskiren/Amlodipine 150/10 mg | Aliskiren/Amlodipine 300/5 mg | Aliskiren/Amlodipine 300/10 mg Tablet | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 53.7 ± 10.32 | 54.3 ± 11.07 | 54.0 ± 9.99 | 54.2 ± 11.61 | 55.0 ± 10.34 | 53.9 ± 10.82 | 53.0 ± 10.59 | 54.8 ± 10.29 | 54.4 ± 10.86 | 54.1 ± 10.65 |
| Sex: Female, Male(Participants) | Placebo | Aliskiren 150 mg | Aliskiren 300 mg | Amlodipine 5 mg | Amlodipine 10 mg | Aliskiren/Amlodipine 150/5 mg | Aliskiren/Amlodipine 150/10 mg | Aliskiren/Amlodipine 300/5 mg | Aliskiren/Amlodipine 300/10 mg Tablet | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 108 | 76 | 108 | 86 | 94 | 84 | 96 | 100 | 78 | 830 |
| Male | 90 | 119 | 95 | 99 | 87 | 97 | 87 | 78 | 106 | 858 |
The record gives a start of Sep 2008, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Aliskiren · Amlodipine